Announcement PDF Appendix 3B - Proposed issue of securities Announcement Summary Entity name AMPLIA THERAPEUTICS LIMITED Announcement Type New announcement Date of this announcement 23/7/2025 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description ATX ORDINARY FULLY PAID Maximum Number of +securities to be issued 1,021,740 Proposed +issue date 29/8/2025 Refer to next page for full details of the announcement Appendix 3B - Proposed issue of securities 1/5 Appendix 3B - Proposed issue of securities Part 1 - Entity and announcement details 1.1 Name of +Entity AMPLIA THERAPEUTICS LIMITED We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules. If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation). 1.2 Registered Number Type Registration Number ABN 16165160841 1.3 ASX issuer code ATX 1.4 The announcement is New announcement 1.5 Date of this announcement 23/7/2025 1.6 The Proposed issue is: A placement or other type of issue Appendix 3B - Proposed issue of securities 2/5 Appendix 3B - Proposed issue of securities Part 7 - Details of proposed placement or other issue Part 7A - Conditions 7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis? Yes 7A.1a Conditions Approval/Condition Date for determination +Security holder approval 27/8/2025 Is the date estimated or actual? ** Approval received/condition met? Actual Comments Director Placement subject to shareholder approval for the purposes of ASX Listing Rule 10.11, to be considered at the Company's Annual General Meeting to be held on Wednesday 27 August 2025. Part 7B - Issue details Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Existing class Will the proposed issue of this +security include an offer of attaching +securities? No Details of +securities proposed to be issued ASX +security code and description ATX : ORDINARY FULLY PAID Number of +securities proposed to be issued 1,021,740 Offer price details Are the +securities proposed to be issued being issued for a cash consideration? Yes In what currency is the cash consideration being paid? What is the issue price per +security? AUD - Australian Dollar AUD 0.23000 Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Appendix 3B - Proposed issue of securities 3/5 Appendix 3B - Proposed issue of securities Yes Part 7C - Timetable 7C.1 Proposed +issue date 29/8/2025 Part 7D - Listing Rule requirements 7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? No 7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? No 7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No 7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? Yes 7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? No 7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? No Part 7E - Fees and expenses 7E.1 Will there be a lead manager or broker to the proposed issue? Yes 7E.1a Who is the lead manager/broker? Bell Potter Securities Limited 7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker? Nil 7E.2 Is the proposed issue to be underwritten? No 7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue Nil - incorporated in fees reported in respect of Placement and SPP referred to in Appendix 3B lodged with the ASX earlier today. Appendix 3B - Proposed issue of securities 4/5 Appendix 3B - Proposed issue of securities Part 7F - Further Information 7F.01 The purpose(s) for which the entity is issuing the securities The Company is undertaking a capital raise which is expected to raise $27.5 million to support the Company's ACCENT and AMPLICITY trials and initiate kRAS and OVARIAN trials of the Company's lead drug, Narmafotinib (AMP 945). 7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No 7F.2 Any other information the entity wishes to provide about the proposed issue The Director Placement referred to herein is being undertaken in conjunction with a Placement, Share Purchase Plan and Conditional Placement to raise gross proceeds of $27.5 million. The Conditional Placement, Director Placement and Share Purchase Plan are conditional on shareholder approval and will be considered at the Company's Annual General Meeting to be held on 27 August 2025. 7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f) Appendix 3B - Proposed issue of securities 5/5